Trial Profile
A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA, MARGINAL ZONE LYMPHOMA AND WALDENSTRÖM MACROGLOBULINEMIA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Roche; Roche Farma
- 08 May 2022 Status changed from recruiting to completed.
- 01 May 2022 Results assessing efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab (eight 21-day cycle as induction therapy) in combination with obinutuzumab , published in the Leukemia and Lymphoma.
- 10 Mar 2022 Planned number of patients changed from 55 to 120.